SEC Form 4 · accession 0001209191-17-054232
MAGELLAN HEALTH INC · MGLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mostafa Kamal
Officer — CEO, Magellan Rx Management
Period of report
Sep 27, 2017
Accepted (ET)
Sep 28, 2017 · 2:45 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000019411
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Common Stock, $0.01 par value | Sep 27, 2017 | X | 11,819 | $60.55 | A | 11,819 | D | |
| Ordinary Common Stock, $0.01 par value | Sep 27, 2017 | X | 7,307 | $64.87 | A | 19,126 | D | |
| Ordinary Common Stock, $0.01 par valueF2 | Sep 27, 2017 | S | 18,526 | $85.3057 | D | 600 | D | |
| Ordinary Common Stock, $0.01 par valueF3 | Sep 27, 2017 | S | 600 | $86.0583 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F5,F4 | $60.55 | Sep 27, 2017 | X | 11,819 | D | — | Aug 3, 2025 | Common Stock | 11,819 | 21,514 | D |
| Stock Option (right to buy)F5,F6 | $64.87 | Sep 27, 2017 | X | 7,307 | D | — | Mar 3, 2026 | Common Stock | 7,307 | 14,613 | D |
Explanation of responses
- F1This transaction was effectuated pursuant to a Rule 10b-5-1 Plan.
- F2The number of securities reported represents an aggregate number of shares sold in multiple open market transactions at prices ranging from $85.00 to $85.975, inclusive. The price reported represents the weighted average price. The Reporting Person undertakes to provide staff of the SEC, the issuer, or a stockholder of the issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.
- F3The number of securities reported represents an aggregate number of shares sold in multiple open market transactions at prices ranging from $86.00 to $86.125, inclusive. The price reported represents the weighted average price. The Reporting Person undertakes to provide staff of the SEC, the issuer, or a stockholder of the issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.
- F4Of the 50,000 stock options granted, 33,333 are currently vested and exercisable. The remainder of 16,666 options shall vest on August 3, 2018.
- F5Not applicable.
- F6Of the 21,920 stock options granted, 7,307 are currently vested and exercisable. The remainder of 14,613 options shall vest in one half increments on March 3 of 2018 and 2019.